SCHEMBL3972161

SCHEMBL3972161

O=C(Nc1ccccc1C(=O)Nc1n[nH]c2sc(C(=O)O)cc12)c1cc[nH]c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.41
POLB P06746 1/20 0.40
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
PKM P14618 1/20 0.39
FGFR1 P11362 1/20 0.38
FGFR2 P21802 1/20 0.38
FGFR3 P22607 1/20 0.38
ATM Q13315 3/20 0.37
ALDH1A1 P00352 3/20 0.37
HTT P42858 2/20 0.37
NPC1 O15118 1/20 0.37
MAPT P10636 1/20 0.37
RAB9A P51151 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
FGFR4 P22455 2/20 0.37
PDE11A Q9HCR9 1/20 0.36
PDE10A Q9Y233 1/20 0.36
CDK7 P50613 1/20 0.36
DHODH Q02127 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3866786 0.90 KDM4E (0.48) KDM4EPOLBKMT2AMEN1PKM
SCHEMBL1780794 0.87 AURKA (0.46) KDM4E
SCHEMBL3872962 0.85 CYP1A2 (0.48) KDM4EPOLBKMT2AMEN1FGFR1
SCHEMBL3871522 0.85 P2RY14 (0.47) KDM4EKMT2AMEN1ATMALDH1A1
SCHEMBL3866073 0.84 HPGD (0.42) KDM4EPOLBKMT2AMEN1PKM
SCHEMBL3872706 0.84 KCNMA1 (0.38) KDM4EPOLBKMT2AMEN1PKM
SCHEMBL3872653 0.84 ALDH1A1 (0.43) KDM4EPOLBKMT2AMEN1ALDH1A1
SCHEMBL3870804 0.84 NPC1 (0.45) KMT2AMEN1PKMALDH1A1HTT
SCHEMBL3872325 0.83 KCNK3 (0.40) KDM4EPOLBKMT2AMEN1PKM
SCHEMBL3866586 0.83 POLB (0.42) KDM4EPOLBKMT2AMEN1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904503-B1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-11-06 EP disclosed
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-06-11 US disclosed
EP-1904503-A1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.r.l. (IT) 2008-04-02 EP disclosed
WO-2007009898-A1 1H-THIENO[2,3-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors CCNH, PDK1, MAP3K5 KDM4E 2856/4885POLB 2784/4885KMT2A 2397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.